Biologic agents commonly used to treat gastrointestinal problems associated with the use of immune checkpoint inhibitors may improve cancer outcomes, results of a two-center retrospective study suggest.
The study, drawn from pooled data from Memorial Sloan Kettering Cancer Center (MSKCC), in New York City, and The University of Texas MD Anderson Cancer Center, in Houston, looked at long-term follow-up in patients taking the integrin inhibitor vedolizumab (Entyvio, Millennium) or the tumor